Expert insight on multiple myeloma management updates from the ASH 2021 annual meeting.
EP. 8: How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka SaysSeptember 5th 2022
Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.